41-50 of 67 results

Allens advises Healthscope on sale of medical centres business
News 05 Sep 2017

Allens has advised Healthscope Limited, one of Australia's leading private healthcare operators, on the sale of its Australian medical centres business to Fullerton Health, a leading provider of ...

Allens advises on Australian-first dementia village
News 19 Jul 2017

Allens has provided pro bono advice to Social Ventures Australia on the financing of the ground-breaking Korongee dementia care village. The first of its kind in Australia, the village is designed ...

Allens advises financiers on Icon Group acquisition
News 25 May 2017

Allens has advised Credit Suisse AG and Goldman Sachs Australia as financiers of the acquisition of the Icon Group, Australia's largest private cancer and oncology services group. The acquisition, ...

Allens advises EBOS Group on acquisition of HPS
News 23 May 2017

Allens has advised EBOS Group Limited on the proposed purchase of HPS, Australia's largest provider of outsourced pharmacy services. The acquisition of HPS - from Blue Sky Private Equity and a numb ...

Allens advises Healthe Care on two major acquisitions
News 08 May 2017

Allens has advised leading Australian private hospital operator Healthe Care Australia in relation to the acquisition of ASX-listed Pulse Health Limited and three hospitals in the Illawarra region ...

ACCC's Enforcement and Compliance priorities for 2017
Insight 27 Feb 2017

Criminal cartels unfair contract terms consumer guarantees and the health construction and agriculture sectors are some of the ACCCs key enforcement and compliance priorities for 2017 ACCC Chairman Rod Sims released the ACCCs 2017 Compliance and Enforcement Policy on Friday 24 February 2017 ...

Assessment of biosimilars - Is Australia leading, following or going its own way?
Insight 26 Oct 2016

The ongoing lack of certainty about what is required to obtain biosimilar registration in Australia extends to three key issues - Comparability is the new product sufficiently similar to permit it to rely on the reference products safety and efficacy data Extrapolation for which of the indications ...

Protecting investment in biologic medicines - biological medicines, biosimilars and the challenges they pose
Insight 15 Sep 2016

This series of articles is directed towards the part of biotech that is pharmaceutical rather than diagnostic or bioengineering technologies and in particular towards biologic medicines ...

What's in a (biosimilar) name?
Insight 08 Sep 2016

Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...

Costs before Caution - Australia's unique approach to the interchangeability of biosimilars
Insight 17 Aug 2016

Recent developments in Australia suggest that there has been a deliberate prioritisation of the cost benefits of facilitating biosimilar interchangeability over the safety and efficacy risks that can arise when biosimilars are used interchangeably ...

Refine